These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15726646)

  • 1. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.
    Schwegler EE; Cazares L; Steel LF; Adam BL; Johnson DA; Semmes OJ; Block TM; Marrero JA; Drake RR
    Hepatology; 2005 Mar; 41(3):634-42. PubMed ID: 15726646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
    Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
    Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
    Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
    Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach.
    Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Chen DS; Yu CY; Wen CL; Lu FJ; Chow LP
    Proteomics; 2006 May; 6(9):2865-73. PubMed ID: 16586433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.
    Kanmura S; Uto H; Kusumoto K; Ishida Y; Hasuike S; Nagata K; Hayashi K; Ido A; Stuver SO; Tsubouchi H
    Hepatology; 2007 Apr; 45(4):948-56. PubMed ID: 17393466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
    Liu XP; Shen J; Li ZF; Yan L; Gu J
    Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
    Wu C; Liu L; Zhao P; Tang D; Yao D; Zhu L; Wang Z
    Gut Liver; 2015 Sep; 9(5):665-71. PubMed ID: 25963079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surface enhanced laser desorption/ionization time-of-flight mass spectrometry profiling of serum in detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis].
    Cheng L; Zhou L; Tao L; Zhang M; Cui JF; Liu YK
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2526-30. PubMed ID: 18067823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and post-treatment changes in the HCC-associated serum proteome.
    Ward DG; Cheng Y; N'Kontchou G; Thar TT; Barget N; Wei W; Martin A; Beaugrand M; Johnson PJ
    Br J Cancer; 2006 Nov; 95(10):1379-83. PubMed ID: 17060939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS.
    Karatayli SC; Alagöz SG; Mizrak D; Sayki M; Ozkan M; Savaş B; Erden E; Cinar K; Idılman R; Yurdaydin C; Bozdayi AM
    Turk J Gastroenterol; 2012 Feb; 23(1):46-53. PubMed ID: 22505379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry coupled with an artificial neural network model for the diagnosis of hepatocellular carcinoma.
    Hu Q; Huang Y; Wang Z; Tao H; Liu J; Yan L; Wang K
    Hepatogastroenterology; 2012 Sep; 59(118):1902-6. PubMed ID: 22193438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.